Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 11,997,606	$ 14,705,008
Accounts receivable, net of allowances of $0 at March 31, 2017 and December 31, 2016, respectively	3,168,756	2,891,723
Deferred costs	3,538,641	3,582,298
Prepaid and other current assets	3,228,845	3,469,932
Total current assets	21,933,848	24,648,961
Property, plant and equipment, net	16,760,376	17,149,241
Goodwill	7,013,315	7,013,315
Intangible assets, net	2,165,380	2,307,880
Other assets	655,503	713,451
Total assets	48,528,422	51,832,848
Current Liabilities
Accounts payable	3,578,045	4,366,753
Accrued liabilities	5,061,813	6,062,569
Liabilities of Business Transferred under Contractual Arrangement, Current	5,000,000	0
Long-term debt, current	3,193,365	3,126,457
Notes payable, current	1,014,495	847,327
Unearned revenues, current	5,364,662	5,098,193
Total current liabilities	23,212,380	19,501,299
Deferred income taxes	1,120,231	1,070,700
Notes payable	215,985	292,217
Unearned revenues - long-term	4,447,397	4,587,397
Long-term debt	1,701,022	2,524,897
Other long-term liabilities	407,241	389,858
Total liabilities	31,104,256	28,366,368
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	19,400,000	19,400,000
Stockholders' Equity (Deficit)
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2017 and December 31, 2016	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 8,953,312 and 8,205,791 shares, at March 31, 2017 and December 31, 2016, respectively	8,953	8,206
Additional paid-in capital	414,056,246	410,372,049
Treasury stock, at cost; 11,080 shares at March 31, 2017 and December 31, 2016, respectively	(707,637)	(707,637)
Accumulated deficit	(414,148,636)	(404,788,809)
Total Caladrius Biosciences, Inc. stockholders' equity (deficit)	(790,974)	4,883,909
Noncontrolling interests	(1,184,860)	(817,429)
Total equity (deficit)	(1,975,834)	4,066,480
Liabilities and Equity, Total	$ 48,528,422	$ 51,832,848